Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 1:08 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2737–2760 of 21,232 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Immunity Disorders Clear all

Conditions: Homosexuality, Male, HIV, Substance-related Disorders, Sexual Dysfunctions, Psychological
Interventions: MyPeeps Manualized Group Intervention, Standard Sexual Health Education; Behavioral
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 16 Years to 20 Years · Male only
Enrollment: 121 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Severe Combined Immunodeficiency Disease, Severe Primary Immunodeficiency Disorder, Undefined T Cell Deficiency Disorder, Wiskott-Aldrick Syndrome
Interventions: Campath -1H, Fludarabine, Anti-CD45, Stem cell infusion; Biological · Drug · Procedure
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Lymphoma
Interventions: bortezomib; Drug
Lead sponsor: NCIC Clinical Trials Group; Network
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 2
States / cities: Hinsdale, Illinois • Philadelphia, Pennsylvania

Conditions: Diffuse Large B Cell Lymphoma
Interventions: Itacitinib, Chimeric antigen receptor (CAR) T-cell therapy; Drug · Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: HIV Infections
Interventions: Popular Opinion Leader; Behavioral
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV)
Interventions: Perianal and Digital Anorectal Exam, Cervical Swabs, Anal Swabs, High Resolution Anoscopy (HRA); Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Sarcoma, Kaposi, HIV Infections
Interventions: Vesnarinone; Drug
Lead sponsor: Otsuka America Pharmaceutical; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Los Angeles, California • Chicago, Illinois

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: therapeutic allogeneic lymphocytes; Biological
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 18 Years to 120 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2009
U.S. locations: 2
States / cities: Boston, Massachusetts • Milwaukee, Wisconsin

Conditions: HIV-infection
Interventions: Angiotensin II Infusion; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections
Interventions: Indinavir sulfate, Amprenavir, Nelfinavir mesylate, Saquinavir; Drug
Lead sponsor: Glaxo Wellcome; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 3
States / cities: San Diego, California • San Francisco, California • Durham, North Carolina

Conditions: HIV Infections, Cytopenias
Interventions: Epoetin alfa; Drug
Lead sponsor: Ortho Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Raritan, New Jersey

Conditions: Atopic Dermatitis
Interventions: Tradipitant, Placebo; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 51
States / cities: Hoover, Alabama • Tempe, Arizona • Encino, California + 43 more

Conditions: HIV Infection
Interventions: OraQuick in home & Sure Check HIV tests; Device
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 2,665 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: HIV -1 Infection, HIV (Human Immunodeficiency Virus), HIV, HIV 1 Infection
Interventions: Bictegravir, emtricitabine, and tenofovir alafenamide; Drug
Lead sponsor: CAN Community Health; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 10
States / cities: Clearwater, Florida • Ft. Pierce, Florida • Jacksonville, Florida + 6 more

Conditions: Systemic Lupus Erythematosus
Interventions: Sifalimumab 200 mg, Sifalimumab 600 mg, Sifalimumab 1,200 mg, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 834 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 17
States / cities: La Jolla, California • Palm Desert, California • San Leandro, California + 14 more

Conditions: Lymphoma
Interventions: MGCD0103; Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 2
States / cities: Durham, North Carolina • Houston, Texas

Conditions: Follicular Lymphoma (FL)
Interventions: Odronextamab, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone/prednisolone, Bendamustine; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 822 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 20
States / cities: Tucson, Arizona • Los Angeles, California • Orange, California + 17 more

Conditions: Rheumatoid Arthritis
Interventions: Study device treatment, Sham device treatment; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: HIV Infections
Interventions: Affect Management, General Health Promotion; Behavioral
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 12 Years to 16 Years
Enrollment: 138 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: HIV Infections
Interventions: HBY 097, Zidovudine; Drug
Lead sponsor: Hoechst Marion Roussel; Industry
Eligibility: 13 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 6
States / cities: Los Angeles, California • Stanford, California • Washington D.C., District of Columbia + 3 more

Conditions: Acute Biphenotypic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Untreated Adult Acute Myeloid Leukemia
Interventions: Laboratory Biomarker Analysis, Liposomal Cytarabine-Daunorubicin CPX-351; Other · Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: Palo Alto, California • Seattle, Washington

Conditions: T-Cell Lymphoma, B-Cell Lymphoma
Interventions: enzastaurin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2018
U.S. locations: 1
States / cities: Anaheim, California

Conditions: HIV Infections
Interventions: Placebo, Aprepitant; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Rheumatoid Arthritis
Interventions: Observational study; Other
Lead sponsor: CARE ARTHRITIS LTD.; Industry
Eligibility: 18 Years and older
Enrollment: 571 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2019
U.S. locations: 5
States / cities: Baltimore, Maryland • New York, New York • Rochester, New York + 1 more

Search by objective public record fields.

HIV Prevention Among Vulnerable Male Youth

Allogeneic SCT Of Pts With SCID And Other Primary Immunodeficiency Disorders

Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia

Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy

ADAPT-POL: Planned Parenthood Center of El Paso Adopting and Demonstrating the Adaptation of Prevention Techniques

New Strategies to Assess Anal Cancer Risk In Women

A Pilot Study of OPC-8212 (Vesnarinone) in Persons With AIDS-Related Kaposi's Sarcoma

Biological Therapy in Treating Patients With Multiple Myeloma That Has Recurred Following Bone Marrow Transplantation

Physiologic Investigation of the Renin Angiotensin Aldosterone Axis in HIV

A Study of 141W94 in Combination With Other Anti-HIV Drugs

A Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up To Determine the Safety and Efficacy of r-HuEPO in AIDS Patients With Anemia Induced by Their Disease and AZT Therapy

Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)

Evaluation of Rapid HIV Self-testing Among MSM (eSTAMP)

REINItiation of Antiretroviral Therapy Using Oral bicTegravir, emtrIcitAbine and Tenofovir alafenamidE

A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus

Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

Ultrasound Treatment of Rheumatoid Arthritis

Affect Management Intervention for Early Adolescents Wtih Mental Health Problems

The Safety and Effectiveness of HBY 097 Used With or Without AZT in HIV-Infected Patients Who Have Mild or No Symptoms

Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia

A Study for Patients With Non-Hodgkin's Lymphomas

Effects of Treatment With Aprepitant (Emend®) in HIV Infected Individuals

Assess Structural Damage in Rheumatoid Arthritis Using Biomarkers and Radiography